Samuel J. Fountain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samuel J. Fountain has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Venketesh Sivaramakrishnan
Disease Biology Lab, Department of Biosciences, Sri Sathya Sai Institute of Higher Learning
4 shared publications - Charles Kennedy
Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK
3 shared publications David Richards
Biomedical Research Centre, School of Biological Sciences University of East Anglia Norwich UK
3 shared publications- Francesco Di Virgilio
University of Ferrara Ferrara Italy
3 shared publications Hinnah Campwala
School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
3 shared publications- Adriaan P. Ijzerman
Leiden University Leiden The Netherlands
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 29 December 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (S1) , S152-S241
The Concise Guide to PHARMACOLOGY 2025/26: Ion channels
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70231 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.
- 29 December 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (S1) , S152-S241
Top Cited PapersOpen AccessThe Concise Guide to PHARMACOLOGY 2025/26: Ion channels
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70231 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.
- Open Access
Assessing Episodic and Semantic Autobiographical Recall in Healthy Older APOE ε4 Carriers
The APOE E4 gene is associated with increased risk of developing sporadic Alzheimer's Disease. Several studies have focused on declarative memory, where episodic memory deficits are reported in E4 carriers, while semantic memory has received much less attention. To clarify whether the impact of APOE E4 on declarative memory is specific to episodic memory, we administered a novel measure of autobiographical memory, the Semantic Autobiographical Interview (SAI). Thirty-eight health older adults were recruited, 19 E4 carriers and 19 non-carriers, matched in age, education, and gender. The groups did not significantly differ in any neuropsychological tests except for recognition memory, where E4 carries showed reduced performance. On the original Autobiographical Interview (AI), results revealed a reduced number of episodic details (internal details and external events) in carriers. Together, these results suggest a reduction of episodic specificity in E4 carriers. In contrast, carriers has very similar semantic production to non-carriers, whether it was for off-task (external) semantic details in the AI, or on-task general and personal semantic details produced in the SAI. These results suggest that older adults retain the gist of their personal experience and that the semanticization of their autobiographical narratives is robust and less sensitive to risk for Alzheimer's Disease than episodic memory.
Open AccessAssessing Episodic and Semantic Autobiographical Recall in Healthy Older APOE ε4 Carriers
The APOE E4 gene is associated with increased risk of developing sporadic Alzheimer's Disease. Several studies have focused on declarative memory, where episodic memory deficits are reported in E4 carriers, while semantic memory has received much less attention. To clarify whether the impact of APOE E4 on declarative memory is specific to episodic memory, we administered a novel measure of autobiographical memory, the Semantic Autobiographical Interview (SAI). Thirty-eight health older adults were recruited, 19 E4 carriers and 19 non-carriers, matched in age, education, and gender. The groups did not significantly differ in any neuropsychological tests except for recognition memory, where E4 carries showed reduced performance. On the original Autobiographical Interview (AI), results revealed a reduced number of episodic details (internal details and external events) in carriers. Together, these results suggest a reduction of episodic specificity in E4 carriers. In contrast, carriers has very similar semantic production to non-carriers, whether it was for off-task (external) semantic details in the AI, or on-task general and personal semantic details produced in the SAI. These results suggest that older adults retain the gist of their personal experience and that the semanticization of their autobiographical narratives is robust and less sensitive to risk for Alzheimer's Disease than episodic memory.
- Open Access
- 25 June 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (21) , 5286-5302
Structure–activity relationship of the allosteric effects of ivermectin at human P2X4 and GABAA receptors
Background and purpose: Positive allosteric modulation of the P2X4 receptor is a potential route to providing cardiovascular benefit through enhancing flow‐dependent arterial vasodilation and providing cardioprotection. However, ligands that selectively enhance P2X4 activity are absent. The broad‐spectrum antiparasitic ivermectin (MK‐933) is a known positive allosteric modulator of P2X4, but not selective for P2X4, acting to enhance the activity of other ion channels including the GABAA receptor through which its neurotoxic and anti‐convulsant properties are mediated. Here, we combine complementary methodology to investigate the structure–activity relationship of ivermectin at human P2X4 and GABAA receptors.Experimental approach and key results: Intracellular Ca2+ and membrane potential assays in cell lines expressing human P2X4 or human GABAA α1β3γ2 receptor are used, respectively. A chemical library of ivermectin analogues are pharmacologically characterised at both receptors, and in silico techniques are used to identify ligand binding modes in human P2X4 to interpret pharmacological properties. We identify ivermectin‐B1a as a positive allosteric modulation of P2X4, but full agonist at the GABAA α1β3γ2 receptor. We discover that the large disaccharide moiety of ivermectin‐B1a is not required for activity. We identify an intersubunit transmembrane domain binding mode for ivermectin‐B1a in P2X4 supported by the structure–activity relationship of ivermectin analogues. A series of novel compounds with selectivity for P2X4 over GABAA receptor are identified.Conclusions and implications: Ivermectin‐B1a enhances P2X4 and GABAA α1β3γ2 receptor activity but through differing pharmacological mechanisms. We identify pharmacophore information for the development of positive allosteric modulators selective for human P2X4 over GABAA receptors.
- 25 June 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (21) , 5286-5302
Open AccessStructure–activity relationship of the allosteric effects of ivermectin at human P2X4 and GABAA receptors
Background and purpose: Positive allosteric modulation of the P2X4 receptor is a potential route to providing cardiovascular benefit through enhancing flow‐dependent arterial vasodilation and providing cardioprotection. However, ligands that selectively enhance P2X4 activity are absent. The broad‐spectrum antiparasitic ivermectin (MK‐933) is a known positive allosteric modulator of P2X4, but not selective for P2X4, acting to enhance the activity of other ion channels including the GABAA receptor through which its neurotoxic and anti‐convulsant properties are mediated. Here, we combine complementary methodology to investigate the structure–activity relationship of ivermectin at human P2X4 and GABAA receptors.Experimental approach and key results: Intracellular Ca2+ and membrane potential assays in cell lines expressing human P2X4 or human GABAA α1β3γ2 receptor are used, respectively. A chemical library of ivermectin analogues are pharmacologically characterised at both receptors, and in silico techniques are used to identify ligand binding modes in human P2X4 to interpret pharmacological properties. We identify ivermectin‐B1a as a positive allosteric modulation of P2X4, but full agonist at the GABAA α1β3γ2 receptor. We discover that the large disaccharide moiety of ivermectin‐B1a is not required for activity. We identify an intersubunit transmembrane domain binding mode for ivermectin‐B1a in P2X4 supported by the structure–activity relationship of ivermectin analogues. A series of novel compounds with selectivity for P2X4 over GABAA receptor are identified.Conclusions and implications: Ivermectin‐B1a enhances P2X4 and GABAA α1β3γ2 receptor activity but through differing pharmacological mechanisms. We identify pharmacophore information for the development of positive allosteric modulators selective for human P2X4 over GABAA receptors.
- Open Access
- 2 February 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (9) , 1975-1988
Characterisation of neurogenic lipolytic responses in white adipose tissue ex vivo
Background and Purpose: Dysfunction of the autonomic nervous system is associated with cardiovascular dysfunction, including metabolic syndrome and obesity. Understanding mechanisms of neurogenic control of white adipose tissue is key to understanding adipose physiology and pathophysiology, though there is limited research exploring this in adipose tissue using pharmacological tools, as opposed to genetic knockout models.Experimental Approach: Inguinal white adipose tissue from C57BL/6J mice was used in this study. We used immunocytochemistry to determine tissue innervation and glycerol release assays to quantify lipolysis in adipose tissue and isolated adipocytes. The voltage‐gated Na+ channel opener veratridine was used to stimulate nervous activity in tissue ex vivo. The role of neurotransmitters and receptors mediating veratridine‐evoked lipolysis in adipose tissue was pharmacologically characterised.Key Results: Veratridine evoked glycerol release in white adipose tissue but not from isolated adipocytes. This release was abolished by tetrodotoxin and propranolol. Veratridine also induced noradrenaline release from white adipose tissue. Veratridine‐ and noradrenaline‐evoked glycerol release was blocked by the β2‐adrenoceptor antagonist ICI‐118551 but not by the β1‐adrenoceptor antagonist CGP 20712A. Purported β3‐adrenoceptor antagonists L‐748337 and SR59230A stimulated glycerol release from tissue and from isolated adipocytes. Neither L‐748337 or SR59230A antagonised veratridine‐evoked glycerol release but SR59230A antagonised noradrenaline‐evoked glycerol release. We exclude contributions of sensory neuropeptides and the autonomic neurotransmitters neuropeptide Y and ATP.Conclusion and Implications: Neurogenic lipolytic responses can be measured in white adipose tissue ex vivo using veratridine to stimulate nerve activity. The lipolytic responses are mediated by β2‐adrenoceptor activation. This study provides the first evidence of neurogenic lipolysis in tissue ex vivo.
- 2 February 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (9) , 1975-1988
Open AccessCharacterisation of neurogenic lipolytic responses in white adipose tissue ex vivo
Background and Purpose: Dysfunction of the autonomic nervous system is associated with cardiovascular dysfunction, including metabolic syndrome and obesity. Understanding mechanisms of neurogenic control of white adipose tissue is key to understanding adipose physiology and pathophysiology, though there is limited research exploring this in adipose tissue using pharmacological tools, as opposed to genetic knockout models.Experimental Approach: Inguinal white adipose tissue from C57BL/6J mice was used in this study. We used immunocytochemistry to determine tissue innervation and glycerol release assays to quantify lipolysis in adipose tissue and isolated adipocytes. The voltage‐gated Na+ channel opener veratridine was used to stimulate nervous activity in tissue ex vivo. The role of neurotransmitters and receptors mediating veratridine‐evoked lipolysis in adipose tissue was pharmacologically characterised.Key Results: Veratridine evoked glycerol release in white adipose tissue but not from isolated adipocytes. This release was abolished by tetrodotoxin and propranolol. Veratridine also induced noradrenaline release from white adipose tissue. Veratridine‐ and noradrenaline‐evoked glycerol release was blocked by the β2‐adrenoceptor antagonist ICI‐118551 but not by the β1‐adrenoceptor antagonist CGP 20712A. Purported β3‐adrenoceptor antagonists L‐748337 and SR59230A stimulated glycerol release from tissue and from isolated adipocytes. Neither L‐748337 or SR59230A antagonised veratridine‐evoked glycerol release but SR59230A antagonised noradrenaline‐evoked glycerol release. We exclude contributions of sensory neuropeptides and the autonomic neurotransmitters neuropeptide Y and ATP.Conclusion and Implications: Neurogenic lipolytic responses can be measured in white adipose tissue ex vivo using veratridine to stimulate nerve activity. The lipolytic responses are mediated by β2‐adrenoceptor activation. This study provides the first evidence of neurogenic lipolysis in tissue ex vivo.
- Open Access
- 20 May 2024
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (6) , 659-667
Pharmacological differences between human and mouse P2X4 receptor explored using old and new tools
There is growing interest in the P2X4 receptor as a therapeutic target for several cardiovascular, inflammatory and neurological conditions. Key to exploring the physiological and pathophysiological roles of P2X4 is access to selective compounds to probe function in cells, tissues and animal models. There has been a recent growth in selective antagonists for P2X4, though agonist selectivity is less well studied. As there are some known pharmacological differences between P2X receptors from different species, it is important to understand these differences when designing a pharmacological strategy to probe P2X4 function in human tissue and mouse models. Here, we provide a systematic comparison of agonist and antagonist pharmacology in 1321N1 cells expressing either human or mouse P2X4 orthologues. We identify a rank order of agonist potency of ATP > 2-MeSATP > αβmeATP = BzATP > CTP = γ-[(propargyl)-imido]-ATP for human P2X4 and ATP > 2-MeSATP = CTP > ATPγS = γ-[(propargyl)-imido]-ATP = BzATP for mouse. Human P2X4 is not activated by ATPγS but can be activated by αβmeATP. We identify a rank order of antagonist potency of BAY-1797 = PSB-12062 = BX-430 > 5-BDBD > TNP-ATP = PPADS for human P2X4 and BAY-1797 > PSB-12062 = PPADS > TNP-ATP for mouse. Mouse P2X4 is not antagonised by 5-BDBD or BX-430. The study reveals key pharmacological differences between human and mouse P2X4, highlighting caution when selecting tools for comparative studies between human and mouse and ascribing cellular responses of some commonly used agonists to P2X4.
- 20 May 2024
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (6) , 659-667
Open AccessPharmacological differences between human and mouse P2X4 receptor explored using old and new tools
There is growing interest in the P2X4 receptor as a therapeutic target for several cardiovascular, inflammatory and neurological conditions. Key to exploring the physiological and pathophysiological roles of P2X4 is access to selective compounds to probe function in cells, tissues and animal models. There has been a recent growth in selective antagonists for P2X4, though agonist selectivity is less well studied. As there are some known pharmacological differences between P2X receptors from different species, it is important to understand these differences when designing a pharmacological strategy to probe P2X4 function in human tissue and mouse models. Here, we provide a systematic comparison of agonist and antagonist pharmacology in 1321N1 cells expressing either human or mouse P2X4 orthologues. We identify a rank order of agonist potency of ATP > 2-MeSATP > αβmeATP = BzATP > CTP = γ-[(propargyl)-imido]-ATP for human P2X4 and ATP > 2-MeSATP = CTP > ATPγS = γ-[(propargyl)-imido]-ATP = BzATP for mouse. Human P2X4 is not activated by ATPγS but can be activated by αβmeATP. We identify a rank order of antagonist potency of BAY-1797 = PSB-12062 = BX-430 > 5-BDBD > TNP-ATP = PPADS for human P2X4 and BAY-1797 > PSB-12062 = PPADS > TNP-ATP for mouse. Mouse P2X4 is not antagonised by 5-BDBD or BX-430. The study reveals key pharmacological differences between human and mouse P2X4, highlighting caution when selecting tools for comparative studies between human and mouse and ascribing cellular responses of some commonly used agonists to P2X4.
- Top Cited PapersOpen Access
- 1 October 2023
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (S2) , S145-S222
The Concise Guide to PHARMACOLOGY 2023/24: Ion channels
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16178. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
- 1 October 2023
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (S2) , S145-S222
Top Cited PapersOpen AccessThe Concise Guide to PHARMACOLOGY 2023/24: Ion channels
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16178. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
- Open Access
- 5 July 2023
- Published by Elsevier in Vascular Pharmacology
- Vol. 151, 107192
Neuropeptide Y: Direct vasoconstrictor and facilitatory effects on P2X1 receptor-dependent vasoconstriction in human small abdominal arteries
- 5 July 2023
- Published by Elsevier in Vascular Pharmacology
- Vol. 151, 107192
Open AccessNeuropeptide Y: Direct vasoconstrictor and facilitatory effects on P2X1 receptor-dependent vasoconstriction in human small abdominal arteries
- Open Access
- 23 November 2022
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (5) , 609-627
STAT1‐ and NFAT‐independent amplification of purinoceptor function integrates cellular senescence with interleukin‐6 production in preadipocytes
Background and Purpose: Senescent preadipocytes promote adipose tissue dysfunction by secreting pro‐inflammatory factors, although little is known about the mechanisms regulating their production. We investigated if up‐regulated purinoceptor function sensitizes senescent preadipocytes to cognate agonists and how such sensitization regulates inflammation.Experimental Approach: Etoposide was used to trigger senescence in 3T3‐L1 preadipocytes. CRISPR/Cas9 technology or pharmacology allowed studies of transcription factor function. Fura‐2 imaging was used for calcium measurements. Interleukin‐6 levels were quantified using quantitative PCR and ELISA. Specific agonists and antagonists supported studies of purinoceptor coupling to interleukin‐6 production. Experiments in MS1 VEGF angiosarcoma cells and adipose tissue samples from obese mice complemented preadipocyte experiments.Key Results: DNA damage‐induced senescence up‐regulated purinoceptor expression levels in preadipocytes and MS1 VEGF angiosarcoma cells. ATP‐evoked Ca2+ release was potentiated in senescent preadipocytes. ATP enhanced interleukin‐6 production, an effect mimicked by ADP but not UTP, in a calcium‐independent manner. Senescence‐associated up‐regulation and activation of the adenosine A3 receptor also enhanced interleukin‐6 production. However, nucleotide hydrolysis was not essential because exposure to ATPγS also enhanced interleukin‐6 secretion. Pharmacological experiments suggested coupling of P2X ion channels and P2Y12–P2Y13 receptors to downstream interleukin‐6 production. Interleukin‐6 signalling exacerbated inflammation during senescence and compromised adipogenesis.Conclusions and Implications: We report a previously uncharacterized link between cellular senescence and purinergic signalling in preadipocytes and endothelial cancer cells, raising the possibility that up‐regulated purinoceptors play key modulatory roles in senescence‐associated conditions like obesity and cancer. There is potential for exploitation of specific purinoceptor antagonists as therapeutics in inflammatory disorders.
- 23 November 2022
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (5) , 609-627
Open AccessSTAT1‐ and NFAT‐independent amplification of purinoceptor function integrates cellular senescence with interleukin‐6 production in preadipocytes
Background and Purpose: Senescent preadipocytes promote adipose tissue dysfunction by secreting pro‐inflammatory factors, although little is known about the mechanisms regulating their production. We investigated if up‐regulated purinoceptor function sensitizes senescent preadipocytes to cognate agonists and how such sensitization regulates inflammation.Experimental Approach: Etoposide was used to trigger senescence in 3T3‐L1 preadipocytes. CRISPR/Cas9 technology or pharmacology allowed studies of transcription factor function. Fura‐2 imaging was used for calcium measurements. Interleukin‐6 levels were quantified using quantitative PCR and ELISA. Specific agonists and antagonists supported studies of purinoceptor coupling to interleukin‐6 production. Experiments in MS1 VEGF angiosarcoma cells and adipose tissue samples from obese mice complemented preadipocyte experiments.Key Results: DNA damage‐induced senescence up‐regulated purinoceptor expression levels in preadipocytes and MS1 VEGF angiosarcoma cells. ATP‐evoked Ca2+ release was potentiated in senescent preadipocytes. ATP enhanced interleukin‐6 production, an effect mimicked by ADP but not UTP, in a calcium‐independent manner. Senescence‐associated up‐regulation and activation of the adenosine A3 receptor also enhanced interleukin‐6 production. However, nucleotide hydrolysis was not essential because exposure to ATPγS also enhanced interleukin‐6 secretion. Pharmacological experiments suggested coupling of P2X ion channels and P2Y12–P2Y13 receptors to downstream interleukin‐6 production. Interleukin‐6 signalling exacerbated inflammation during senescence and compromised adipogenesis.Conclusions and Implications: We report a previously uncharacterized link between cellular senescence and purinergic signalling in preadipocytes and endothelial cancer cells, raising the possibility that up‐regulated purinoceptors play key modulatory roles in senescence‐associated conditions like obesity and cancer. There is potential for exploitation of specific purinoceptor antagonists as therapeutics in inflammatory disorders.
- Open Access
- 3 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8646
Transcriptional and Post-Translational Regulation of Junctional Adhesion Molecule-B (JAM-B) in Leukocytes under Inflammatory Stimuli
Junctional adhesion molecules (JAMs; comprising JAM-A, -B and -C) act as receptors for viruses, mediate cell permeability, facilitate leukocyte migration during sterile and non-sterile inflammation and are important for the maintenance of epithelial barrier integrity. As such, they are implicated in the development of both communicable and non-communicable chronic diseases. Here, we investigated the expression and regulation of JAM-B in leukocytes under pathogen- and host-derived inflammatory stimuli using immunoassays, qPCR and pharmacological inhibitors of inflammatory signalling pathways. We show that JAM-B is expressed at both the mRNA and protein level in leukocytes. JAM-B protein is localised to the cytoplasm, Golgi apparatus and in the nucleus around ring-shaped structures. We also provide evidence that JAM-B nuclear localisation occurs via the classical importin-α/β pathway, which is likely mediated through JAM-B protein nuclear localisation signals (NLS) and export signals (NES). In addition, we provide evidence that under both pathogen- and host-derived inflammatory stimuli, JAM-B transcription is regulated via the NF-κB-dependent pathways, whereas at the post-translational level JAM-B is regulated by ubiquitin-proteosome pathways. Anaphase-promoting ubiquitin ligase complex (APC/C) and herpes simplex virus-associated ubiquitin-specific protease (HAUSP/USP) were identified as candidates for JAM-B ubiquitination and de-ubiquitination, respectively. The expression and regulation of JAM-B in leukocytes reported here is a novel observation and contrasts with previous reports. The data reported here suggest that JAM-B expression in leukocytes is under the control of common inflammatory pathways.
- 3 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8646
Open AccessTranscriptional and Post-Translational Regulation of Junctional Adhesion Molecule-B (JAM-B) in Leukocytes under Inflammatory Stimuli
Junctional adhesion molecules (JAMs; comprising JAM-A, -B and -C) act as receptors for viruses, mediate cell permeability, facilitate leukocyte migration during sterile and non-sterile inflammation and are important for the maintenance of epithelial barrier integrity. As such, they are implicated in the development of both communicable and non-communicable chronic diseases. Here, we investigated the expression and regulation of JAM-B in leukocytes under pathogen- and host-derived inflammatory stimuli using immunoassays, qPCR and pharmacological inhibitors of inflammatory signalling pathways. We show that JAM-B is expressed at both the mRNA and protein level in leukocytes. JAM-B protein is localised to the cytoplasm, Golgi apparatus and in the nucleus around ring-shaped structures. We also provide evidence that JAM-B nuclear localisation occurs via the classical importin-α/β pathway, which is likely mediated through JAM-B protein nuclear localisation signals (NLS) and export signals (NES). In addition, we provide evidence that under both pathogen- and host-derived inflammatory stimuli, JAM-B transcription is regulated via the NF-κB-dependent pathways, whereas at the post-translational level JAM-B is regulated by ubiquitin-proteosome pathways. Anaphase-promoting ubiquitin ligase complex (APC/C) and herpes simplex virus-associated ubiquitin-specific protease (HAUSP/USP) were identified as candidates for JAM-B ubiquitination and de-ubiquitination, respectively. The expression and regulation of JAM-B in leukocytes reported here is a novel observation and contrasts with previous reports. The data reported here suggest that JAM-B expression in leukocytes is under the control of common inflammatory pathways.
- 1 January 2022
- Published by Elsevier in Molecular Pharmacology
- Vol. 101 (1) , 33-44
Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors
The P2X4 receptor is a ligand-gated ion channel activated by extracellular ATP. P2X4 activity is associated with neuropathic pain, vasodilation and pulmonary secretion and therefore of therapeutic interest. The structure-activity relationship of P2X4 antagonists is poorly understood. Here we elucidate the structure-activity of 5-BDBD at human P2X4 by combining pharmacology, electrophysiology, molecular modelling and medicinal chemistry. 5-BDBD antagonised P2X4 in a non-competitive manner but lacked effect at human P2X2. Molecular modelling and site-directed mutagenesis suggested an allosteric binding site for 5-BDBD located between two subunits in the body region of P2X4, with M109, F178, Y300 and I312 on one subunit, and R301 on the neighbouring subunit as key residues involved in antagonist binding. The bromine group of 5-BDBD was redundant for the antagonist activity of 5-BDBD, though an interaction between the carbonyl group of 5-BDBD and R301 in P2X4 was significantly associated with 5-BDBD activity. 5-BDBD could inhibit the closed channel but poorly inhibited the channel in the open/desensitising state. We hypothesize that this is due to constriction of the allosteric site following transition from closed to open channel state. We propose that M109, F178, Y300, R301 and I312 are key residues for 5-BDBD binding, provide a structural explanation of how they contribute to 5-BDBD antagonism, and highlight that the limited action of 5-BDBD on open versus closed channels is due to a conformational change in the allosteric site. Significance Statement Activity of P2X4 receptor is associated with neuropathic pain, inflammation and vasodilatation. Molecular information regarding small molecule interaction with P2X4 is very limited. Here we provide a structural explanation for the action of the small molecule antagonist 5-BDBD at the human P2X4 receptor.
- 1 January 2022
- Published by Elsevier in Molecular Pharmacology
- Vol. 101 (1) , 33-44
Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors
The P2X4 receptor is a ligand-gated ion channel activated by extracellular ATP. P2X4 activity is associated with neuropathic pain, vasodilation and pulmonary secretion and therefore of therapeutic interest. The structure-activity relationship of P2X4 antagonists is poorly understood. Here we elucidate the structure-activity of 5-BDBD at human P2X4 by combining pharmacology, electrophysiology, molecular modelling and medicinal chemistry. 5-BDBD antagonised P2X4 in a non-competitive manner but lacked effect at human P2X2. Molecular modelling and site-directed mutagenesis suggested an allosteric binding site for 5-BDBD located between two subunits in the body region of P2X4, with M109, F178, Y300 and I312 on one subunit, and R301 on the neighbouring subunit as key residues involved in antagonist binding. The bromine group of 5-BDBD was redundant for the antagonist activity of 5-BDBD, though an interaction between the carbonyl group of 5-BDBD and R301 in P2X4 was significantly associated with 5-BDBD activity. 5-BDBD could inhibit the closed channel but poorly inhibited the channel in the open/desensitising state. We hypothesize that this is due to constriction of the allosteric site following transition from closed to open channel state. We propose that M109, F178, Y300, R301 and I312 are key residues for 5-BDBD binding, provide a structural explanation of how they contribute to 5-BDBD antagonism, and highlight that the limited action of 5-BDBD on open versus closed channels is due to a conformational change in the allosteric site. Significance Statement Activity of P2X4 receptor is associated with neuropathic pain, inflammation and vasodilatation. Molecular information regarding small molecule interaction with P2X4 is very limited. Here we provide a structural explanation for the action of the small molecule antagonist 5-BDBD at the human P2X4 receptor.